Achillion Pharmaceuticals, Inc., a biopharmaceutical company,
discovers, develops, and commercializes anti-infective drug therapies in
the United States and internationally. It focuses on developing
combination therapies for the treatment of chronic hepatitis C (HCV)
infection and resistant bacterial infections. The company’s drug
candidates for treating chronic HCV infection comprise Sovaprevir, a
NS3/4A protease inhibitor, which has completed a Phase IIa clinical
trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial;
ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed
preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has
completed Phase Ia and Ib clinical trials. It has a license and
development agreement with Ora, Inc. for the development and
commercialization of ACH-702, an antibacterial drug candidate that is
delivered topically or locally.
Take a look at the 1-year chart of Achillion (Nasdaq: ACHN) with added notations:
After trading between $2 and $4 from October through May, ACHN shot
up to hit a new high of $8.50 in June, and then sold off into July.
Since that time, the stock has rallied back up to the $8.50 resistance
(red) and appears to have now formed the cup (blue) portion of a
potential cup and handle pattern. Regardless if the stock forms the
handle or not, the stock should be headed higher if it breaks through
resistance.
The Tale of the Tape: ACHN may have formed the cup
in a C&H pattern. A long trade should be entered on a breakout above
the $8.50 level with a stop placed under that level.
Please share this article
No comments:
Post a Comment